nsclc

How do rare driver gene mutations in non-small cell lung cancer relate to age?
Non-small cell lung cancer Genetic mutations nsclc lung cancer
05-10
JITC: Blood TMB is expected to be a predictive biomarker for immunotherapy for lung cancer
tmb immunity lung cancer tumor nsclc btmb
05-01
The AACR Conference opened today, what progress is worth paying attention to?
Multiple myeloma WuXi AppTec tumor blueprint medicines c4 therapeutics nsclc pd-1 clone treat American Association for Cancer Research
04-09
Whether lung cancer patients should use immunotherapy after surgery has new evidence
lung cancer immunity chemotherapy Non-small cell lung cancer nsclc
04-06
The latest research progress of six rare targets of lung cancer, an inventory
lung cancer nsclc Non-small cell lung cancer cancer Li Guoyu Zhou Caicun Wu Fengying hospital He Ming ramalingam
04-03
Lung cancer rare target therapy has advanced rapidly, and patients are no longer "afraid" because of "rare"
lung cancer nsclc Non-small cell lung cancer treat
03-26
Latest Advances in Targeted Therapy! Lung Cancer Chief Specialist Tension: Lung cancer targeted therapy ushered in a new milestone
lung cancer nsclc Non-small cell lung cancer Darafenib Trimetinib tumor
03-25
In patients with pulmonary sarcoma-like carcinoma, MET inhibitors bring new options to treatment
Lung sarcoma depressor tumor nsclc cancer treat
03-21
Although there is an EGFR mutation, targeted drugs are not recommended in this case and do not necessarily benefit from use
egfr Targeted drugs lung cancer Oscitinib chemotherapy nsclc
03-15
Review the approval of these blockbuster targeted drugs for lung cancer in 2021
lung cancer Targeted drugs Oscitinib Pratinifib with nothing nsclc Indications chemotherapy Severatinib
03-04
Read in one article: ADAURA study
Oscitinib adaura nsclc
02-23
Treatment options for adjuvant-targeted therapy in patients with EGFR mutation-positive NSCLC after relapse
egfr nsclc egfr-tki lung cancer
02-21
EGFR mutation-positive NSCLC patients adjuvant targeted therapy concerned with DFS or OS?
egfr nsclc masculine
02-18
Adjunctive targeted therapy in patients with EGFR mutation-positive NSCLC 2 years or 3 years?
egfr nsclc masculine egfr-tki
02-16
NCCN Guidelines: Targeted, Immune How to Treat Phase I-III NSCLC
nsclc immunity NCCN Guidelines Duvalliizumab chemotherapy
02-14
Panshengzi and Huang Pharmaceutical have reached a cooperation agreement with Huang Pharmaceutical on the concomitant diagnosis of Verisa for non-small cell lung cancer
Pan-oxon Voressa and Huang Medicine Non-small cell lung cancer lung cancer nsclc
02-10
The first day of prescription of sugliformumab in Guangdong will benefit more lung cancer patients
Choose Jiemei Schuglizumab lung cancer tumor nsclc
01-14
2022 NCN Guidelines for Lung Cancer: Rare Mutations Have New Targeted Drug Recommendations
lung cancer NCCN Guidelines Targeted drugs her2 breast cancer nsclc
01-09
【News】The clinical trial of loratinib for ROS1-positive advanced NSCLC was approved in China
Loratinib nsclc CStone Pharmaceuticals Non-small cell lung cancer
01-04
CStone's application for a critical clinical trial of loratinib was approved in China
Loratinib CStone Pharmaceuticals nsclc Non-small cell lung cancer
01-04